JinG, ShiH, DuJ, et al.Pre-exposure prophylaxis care continuum for HIV risk populations: An umbrella review of systematic reviews and meta-analyses. AIDS Patient Care STDS, 2023; 37(12):583–615; doi: 10.1089/apc.2023.0158
2.
HuangY, TianR, ZhouZ, et al.HIV pre-exposure prophylaxis use on a global scale among men who have sex with men: A systematic review and meta-analysis. AIDS Patient Care STDS, 2023; 37(4):159–191; doi: 10.1089/apc.2022.0198
3.
DeanLT, PredmoreZ, SkinnerA, et al.Optimizing uptake of long-acting injectable pre-exposure prophylaxis for HIV prevention for men who have sex with men. AIDS Behav, 2023; 27(8):2606–2616; doi: 10.1007/s10461-023-03986-5
4.
ZarwellM, WittB, Marin-CespedesS, et al.Uptake and discontinuation of pre-exposure prophylaxis among uninsured transgender and cisgender women: A public-private partnership model in North Carolina. AIDS Patient Care STDs, 2023; 37(11):525–534; doi: 10.1089/apc.2023.0147
5.
DangM, ScheimAI, TetiM, et al.Barriers and facilitators to HIV pre-exposure prophylaxis uptake, adherence, and persistence among transgender populations in the United States: A systematic review. AIDS Patient Care STDS, 2022; 36(6):236–248; doi: 10.1089/apc.2021.0236
6.
HughtoJMW, FernandezY, RestarA, et al.High awareness but low uptake of pre-exposure prophylaxis in a community sample of trans masculine adults in Massachusetts. AIDS Patient Care STDS, 2022; 36(7):249–253; doi: 10.1089/apc.2022.0080
7.
ShawG, SchaeferR, SchmidtH-MA, et al.Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: A global mapping of service delivery. Harm Reduct J, 2023; 20(1):16; doi: 10.1186/s12954-023-00729-6
8.
Clarke-SteffenL, ChulaniV, DobbsM, et al.Barriers encountered by youth aged 13–24 while accessing pre-exposure prophylaxis to HIV: Phoenix Pre-Exposure Prophylaxis Access Project. AIDS Patient Care STDs, 2023; 37(9):432–435; doi: 10.1089/apc.2023.0131
9.
FuscoN, SilsB, GraffJS, et al.Cost-sharing and adherence, clinical outcomes, health care utilization, and costs: A systematic literature review. J Manag Care Spec Pharm, 2023; 29(1):4–16; doi: 10.18553/jmcp.2022.21270
DeanLT, NunnAS, ChangH-Y, et al.Estimating the impact of out-of-pocket cost changes on abandonment of HIV pre-exposure prophylaxis. Health Aff (Millwood), 2024; 43(1):36–45; doi: 10.1377/hlthaff.2023.00808
340B drug pricing program. Available from: https://www.hrsa.opa [Last accessed: May21, 2024].
14.
FilipI. Changing costs of preexposure prophylaxis may undermine efforts to curb HIV infection rates. Aids, 2024; 38(7):N11–N12; doi: 10.1097/QAD.0000000000003883
15.
DevlinSA, RidgwayJP, DawdaniA, et al.Adapting provider training and pre-exposure prophylaxis advertising to increase pre-exposure prophylaxis awareness and uptake among Black cisgender women. AIDS Patient Care STDS, 2023; 37(12):574–582; doi: 10.1089/apc.2023.0188
16.
AndradeEA, BetancourtG, MoralesG, et al.A community-based pre-exposure prophylaxis telehealth program focused on Latinx sexual minority men. AIDS Patient Care STDS, 2023; 37(11):517–524; doi: 10.1089/apc.2023.0185
